Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, et al.
Science (2023) Vol. 381, Iss. 6659, pp. 794-799
Open Access | Times Cited: 117
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1556-1571
Open Access | Times Cited: 103
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 42
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1102-1120
Open Access | Times Cited: 33
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16173-16203
Closed Access | Times Cited: 65
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Annual review of KRAS inhibitors in 2022
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115124-115124
Closed Access | Times Cited: 32
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 24
Development of covalent inhibitors: Principle, design, and application in cancer
Lang Zheng, Yang Li, Defa Wu, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 24
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 9, pp. 1017-1029
Closed Access | Times Cited: 22
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
Alok K. Sharma, Jun Pei, Yue Yang, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 2, pp. 105650-105650
Open Access | Times Cited: 10
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Simon Manuel Tria, Matthew Burge, Vicki Whitehall
Cancers (2023) Vol. 15, Iss. 8, pp. 2375-2375
Open Access | Times Cited: 20
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103557-103557
Closed Access | Times Cited: 18
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration
Jason G. Kettle, Sharan K. Bagal, Derek Barratt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9147-9160
Closed Access | Times Cited: 16
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5079-5079
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top